Find the article here.

Addressing the Multiple Challenges  of Antimicrobial Resistance

Public awareness is growing in Canada and around the world about the urgent need for concerted global action to counter the serious health threat posed by antimicrobial resistance (AMR). 

...

EDMONTON, Alberta – January 16, 2017 – Fedora Pharmaceuticals, Inc. announced they have received nonrefundable financial contribution from the National Research Council of Canada’s Industrial Research Assistance Program (NRC-IRAP). In addition to tec...

Doctors around the world are starting to speak with one voice with regards to superbugs, those ever-evolving, antibiotic-resistant bacteria with the potential to do significant harm to humans.

In hospitals in particular: patients are admitted with one...

Antimicrobials, and specifically antibiotics, play a crucial role in modern medicine. These precious medicines are often taken for granted and are not only necessary to treat life-threatening infections, but are also vital to underpin most common sur...

Fedora Pharmaceuticals Receives Alberta Life Sciences "Company of the Year" Award EDMONTON, Alberta – November 30, 2015 – Fedora Pharmaceuticals, Inc. today announced that it was named "Company of the Year" by BioAlberta during the Association's 16th...

EDMONTON, Alberta – November 9, 2015 – Fedora Pharmaceuticals Inc., a biotechnology company headquartered in Edmonton, Alberta, Canada, announced their receipt of the 2015 Outstanding Commercial Achievement in Alberta Science and Technology award fro...

 Roche licenses investigational beta-lactamase inhibitor OP0595

 OP0595 targets beta-lactamase enzymes in combination with new or existing beta-lactam antibiotics to enhance their effectiveness in difficult-to-treat bacterial infections

Roche (SIX: R...

Findings Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

EDMONTON, Alberta – September 12, 2013 – Fedora Pharmaceuticals, Inc. and its collaborators presented results of preclinical studies demonstrating that FPI...

EDMONTON, Alberta – October 31, 2012 – Fedora Pharmaceuticals, Inc. today announced the creation of a Board of Directors and appointment of Leonard E. Post, Ph.D. and Ronald W. Odynski, Q.C. as directors. The Board will be chaired by Christopher Mice...